Building a Pipeline of Therapies to Treat Rare Mineralization Disorders

Axel Bolte, co-founder and CEO of Inozyme, discusses ENPP1 deficiency, the company's lead experimental therapy to treat the condition, and its work with Rady Children’s Institute for Genomic Medicine to improve the diagnosis of newborns with the disease.